Email this article Unsolved issues of treatment of adult patients with hemophilia A
- Authors: Zozulya N.I.1, Dimitrieva O.S.1
-
Affiliations:
- National Research Center for Hematology
- Issue: Vol 94, No 1 (2022)
- Pages: 77-82
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/104766
- DOI: https://doi.org/10.26442/00403660.2022.01.201321
- ID: 104766
Cite item
Full Text
Abstract
Background. Sufficient supply of coagulation factors products has significantly improved life quality and expectancy in patients with hemophilia. Certain difficulties, however, persist when it comes to the treatment of the disease.
Aim. To analyze current therapeutic approaches and identify major unsolved issues in the treatment of patients with hemophilia A.
Materials and methods. An online survey of 100 adult patients with hemophilia A was held.
Results. More than a half of the surveyed sample (59%) are patients aged 19 to 40 with the severe form of the disease, 73% of respondents receive a replacement therapy with plasmatic factors, 42% of patients inject drugs 3 times a week or more. More than a half of all age groups with hemophilia have persistent pain and limited joint mobility, in 70% of the patients, bleeding into the joints occurred 4 or more times within the past year, 47% of the patients with hemophilia A are partially satisfied or dissatisfied with their state of health, 92% of the patients would like to improve their quality of life. At the same time, about 1/3 of the patients would like to reduce the frequency of drug administration. More than 40% of the respondents did not visit a hematologist during the year, 85% do not conduct regular laboratory monitoring.
Conclusion. The survey results demonstrate numerous areas of potential change pertaining to the approaches towards therapy and to the innovative drugs for the treatment of patients with hemophilia.
Full Text
##article.viewOnOriginalSite##About the authors
Nadezhda I. Zozulya
National Research Center for Hematology
Author for correspondence.
Email: zozulya.n@blood.ru
ORCID iD: 0000-0001-7074-0926
д-р мед. наук, зав. отд. коагулопатий
Russian Federation, MoscowOksana S. Dimitrieva
National Research Center for Hematology
Email: zozulya.n@blood.ru
ORCID iD: 0000-0001-6430-1740
врач-гематолог отд. коагулопатий
Russian Federation, MoscowReferences
- Воробьев П.А., Краснова Л.С., Воробьев А.П., и др. Эпидемиология, экономика и качество жизни больных с гемофилией в России 2007–2017 гг.: результаты применения стандартизации в терапии. Проблемы стандартизации в здравоохранении. 2018;9-10 [Vorobyev PA, Krasnova LS, Vorobyev AP, et al. Epidemiology, economics and quality of life of patients with hemophilia in Russia for 2007–2017: results of standardization use in therapy. Problems of Standardization in Healthcare. 2018;9-10 (in Russian)].
- Nugent D, O'Mahony B, Dolan G. Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia. Haemophilia. 2018;24(5):755-65.
- Oak B, Nambiar S, Springs S, Eguale T. A Comparison of Prophylactic Versus On-Demand Treatment Regimens of Coagulation Factor VIII for Bleeding and Joint Outcomes in Hemophilia a Patients Without Inhibitors: A Systematic Review and Meta-Analysis. Value Heal. 2018;21:S247. doi: 10.1016/j.jval.2018.04.1672
- Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20(11):759-74.
- Srivastava AK, Brewer EP, Bunschoten M. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):1-47.
- Румянцев А.Г., Румянцев С.А., Чернов В.М. Гемофилия в практике врачей различных специальностей. М.: ГЭОТАР-Медиа, 2012 [Rumyantsev AG, Rumyantsev SA, Chernov VM. Gemofiliia v praktike vrachei razlichnykh spetsial'nostei. Moscow: GEOTAR-Media, 2012 (in Russian)].
- O'Hara S, Castro FA, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia. 2021;27:113-9.
- Von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients' unmet needs and their expectations. Haemophilia. 2017;23:566-74.
- Давыдкин И.Л., Косякова Ю.А., Ларцев Ю.В., Капишников А.В. Оценка воспалительных изменений в суставах у больных гемофилией с рецидивирующими гемартрозами. Травматология и ортопедия России. 2012;2(64) [Davydkin IL, Kosyakova YuA, Lartsev YuV, Kapishnikow AV. Evaluation of inflammatory changes in joints at patients with hemophilia accompanied recurrent hemarthrosis. Traumatology and Orthopedics of Russia. 2012;2(64) (in Russian)].
- Зозуля Н.И., Кумскова М.А., Полянская Т.Ю., Свирин П.В. Клинические рекомендации по диагностике и лечению гемофилии. НГО. 2018 [Zozulya NI, Kumskova MA, Polyanskaya TYu, Svirin PV. Clinical guidelines for the diagnosis and treatment of hemophilia. NGO, 2018 (in Russian)].
- Солдатов А.А., Авдеева Ж.И., Мосягин В.Д., и др. Основные направления по разработке и модификации препаратов для лечения гемофилии. Гематология и трансфузиология. 2016;61(4):208-15 [Soldatov AA, Avdeeva ZhI, Mosyagin VD, et al. Main directions for the development and modification of preparations for the treatment of hemophilia. Hematology and Transfusiology. 2016;61(4):208-15 (in Russian)]. doi: 10.18821/0234-5730-2016-61-4-208-215
- Marchesini E, Morfini M, Valentino L. Real world advances in the treatment of hemophilia: a review. Biologics: targets and therapy, 15 June 2021.
- European medicines agency. Hemlibra. Assessment report (25 January 2018).
- New data for Roche's Hemlibra reinforce safety profile in people with hemophilia A. Available at: Roche.com. Accessed: 24.11.2021.
- Wall C, Xiang H, Palmer B, et al. Real world efficacy of emicizumab prohilaxis in hemophilia A with inhibitors. A report from the UK National haemophilia database. Res Pract Thromb Haemost. 2020;4(Suppl 1).
Supplementary files
